EIP Pharma is a clinical stage therapeutics company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process.
We believe the neurodegenerative process is, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a treatment for early Alzheimer’s disease, dementia with Lewy Bodies, and Huntington’s disease.
We have assembled a highly experienced executive management team led by our two co-founders, board of directors and scientific advisory board to execute on our mission to develop and commercialize innovative drug treatments for Alzheimer’s disease and other central nervous system disorders. Our management team is led by our Co-Founders, John Alam, MD and Sylvie Grégoire, PharmD.
EIP Pharma in the News
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer’s Disease
November 7, 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)